Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation-Reference-Cited by-同舟云学术

Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation

Published:2007-05 Issue:4 Volume:137 Page:349-354
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Nishio Mitsufumi,Fujimoto Katsuya,Yamamoto Satoshi,Endo Tomoyuki,Sakai Toshiya,Obara Masato,Kumano Kohki,Yamaguchi Keisuke,Takeda Yukari,Goto Hideki,Sato Norihiro,Koizumi Kazuki,Mukai Masaya,Koike Takao

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06584.x/fullpdf

Reference23 articles.

1. Absence of Memory B Cells in Patients with Common Variable Immunodeficiency

2. Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5+B Cells

3. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

4. Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors for Persistent Hypogammaglobulinemia After Rituximab Therapy in Pediatric Patients;2024-05-30

2. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients;Frontiers in Neurology;2024-04-18

3. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management;Multiple Sclerosis and Related Disorders;2023-11

4. Secondary rituximab‐associated versus primary immunodeficiencies: The enigmatic border;European Journal of Immunology;2022-08-10

5. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency;Expert Review of Clinical Immunology;2020-07-02